Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer
Status:
Terminated
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Gefitinib may stop the growth of kidney cancer by blocking blood flow to the tumor
and by blocking some of the enzymes needed for cell growth. PEG-interferon alfa-2b may
interfere with the growth of tumor cells and slow the growth of kidney cancer. Giving
gefitinib together with PEG-interferon alfa-2b may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving gefitinib together with
PEG-interferon alfa-2b works in treating patients with unresectable or metastatic kidney
cancer.